Dynavax nets $70.5mm through public stock sale

15:40 EDT 11 Aug 2017 | Elsevier Business Intelligence

Dynavax Technologies Corp. (immunotherapies for infectious, autoimmune, and inflammatory diseases, and cancer) netted $70.5mm...

Original Article: Dynavax nets $70.5mm through public stock sale


More From BioPortfolio on "Dynavax nets $70.5mm through public stock sale"

Quick Search

Relevant Topics

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...